Methods of blocking tissue destruction by autoreactive T cells
First Claim
1. A method for inhibiting autoreactive T cell-initiated destruction of tissues in a mammal comprising:
- administering a pharmaceutical composition to the mammal, said pharmaceutical composition comprising an agent selected from the group consisting of;
an isolated HSA/CD24 polypeptide, an isolated biologically active fragment of an HSA/CD24 polypeptide, a fusion protein comprising an HSA/CD24 polypeptide, a fusion protein comprising a biologically active fragment of an HSA/CD24 polypeptide, and an anti-HSA/CD24 antibody;
wherein said pharmaceutical composition is administered in an amount sufficient to reduce autoreactive T cell-initiated tissue destruction in said mammal.
1 Assignment
0 Petitions
Accused Products
Abstract
Methods for blocking autoreactive T cell-initiated destruction of tissues in a mammal are provided. In one embodiment, the method comprises administering a purified CD24 polypeptide, a fusion protein comprising such polypeptide, or a biologically active fragment of such polypeptide to a mammalian subject who is suspected of having or predisposed to having an autoimmune disease. In another embodiment, anti-CD24 antibody or anti-CD24 Fab fragments are administered to the subject. In another embodiment, the method comprises administering a CD24 antisense molecule, an expression vector encoding a CD24 antisense molecule, CD24 dsRNAi, or an expression vector encoding CD24 dsRNAi to the subject. The present invention also relates to isolated and purified CD24 fusion proteins employed in the present methods and to transgenic mice that express the human CD24 protein on their T cells and/or their vascular endothelial cells but do not express murine heat shock antigen on any cells.
-
Citations
28 Claims
-
1. A method for inhibiting autoreactive T cell-initiated destruction of tissues in a mammal comprising:
administering a pharmaceutical composition to the mammal, said pharmaceutical composition comprising an agent selected from the group consisting of;
an isolated HSA/CD24 polypeptide, an isolated biologically active fragment of an HSA/CD24 polypeptide, a fusion protein comprising an HSA/CD24 polypeptide, a fusion protein comprising a biologically active fragment of an HSA/CD24 polypeptide, and an anti-HSA/CD24 antibody;
wherein said pharmaceutical composition is administered in an amount sufficient to reduce autoreactive T cell-initiated tissue destruction in said mammal.- View Dependent Claims (2, 7, 8, 9, 14)
-
3. A method for treating a patient suspected of having, known to have, or predisposed to having an autoimmune disease, said method comprising.
administering to said patient a pharmaceutical composition comprising an agent selected from the group consisting of an HAS/CD24 polypeptide, an isolated biologically active fragment of an HSA/CD24 polypeptide, a fusion protein comprising an HSA/CD24 polypeptide, a fusion protein comprising a biologically active fragment of an HSA/CD24 polypeptide, and an anti-HSA/CD24 antibody.
- 10. A fusion protein comprising human IgG 1 Fc and human CD24 polypeptide or the core fragment thereof.
-
13. A transgenic mouse whose genome comprises a polynucleotide encoding human CD24 polypeptide, wherein said polynucleotide is operably linked to a promoter;
- and wherein said transgenic mouse expresses human CD24 on the surface of its T cells.
- View Dependent Claims (15)
-
16. A method of blocking binding of autoreactive T cells to vascular endothelial cells, comprising:
contacting said vascular endothelial cells with an agent selected from the group consisting of an isolated HSA/CD24 polypeptide, an isolated biologically active fragment of an HSA/CD24 polypeptide, a fusion protein comprising an HSA/CD24 polypeptide, a fusion protein comprising an biologically fragment of an HSA/CD24 polypeptide, and an anti-HSA/CD24 antibody, wherein said cells are contacted with a sufficient amount of said agent to inhibit interaction of the autoreactive T cells with the vascular endothelial cells. - View Dependent Claims (17)
-
18. A method of reducing autoreactive T cell-initiated destruction of tissues in a mammal, comprising:
- administering to the mammal an agent that reduces interaction of the CD24 polypeptide that is present on the autoreactive T cells with a functional ligand of the CD24 polypeptide.
- View Dependent Claims (19, 20, 21, 22, 23, 24, 25, 26, 27)
-
28. A method for inhibiting autoreactive T cell-initiated destruction in a mammal by targeting CD24 molecules at genomic, transcription, post-transcriptional, translational and ligand binding levels, the method comprising:
-
administering a pharmaceutical composition to the mammal, said pharmaceutical composition comprising an agent selected from the group consisting of an isolated HSA/CD24 polypeptide, an isolated biologically active fragment of an HSA/CD24 polypeptide, a fusion protein comprising an HSA/CD24 polypeptide, a fusion protein comprising a biologically active fragment of an HSA/CD24 polypeptide, an anti-HSA/CD24 antibody, a CD24 antisense molecule, a polynucleotide encoding a CD24 antisense molecule, a CD24 dsRNAi molecule and a polynucleotide encoding a CD24 dsRNAi molecule;
wherein said pharmaceutical composition is administered in an amount sufficient to reduce autoreactive T cell-initiated tissue destruction in said mammal.
-
Specification